Evaluation of Dry Eyes
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage and clinical guidance for diagnostic testing used to evaluate dry eye disease (DED), specifying which tear biomarkers and osmolarity tests meet or do not meet coverage criteria for Oscar Health members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Dry Eye Diagnostic Testing
inv-01: Tear osmolarity testing — Covered when ANY of the following are met:
Covered when ANY of the following are met:
Point-of-care osmolarity systems (e.g., TearLab, ScoutPro) are referenced; osmolarity should be interpreted in the context of other clinical assessments due to variability in measurements.
inv-02: Biomarker testing (MMP-9, lactoferrin, IgE) and other tests — Not covered / Do not meet criteria
Not covered / Do not meet criteria:
AAO notes MMP-9 does not differentiate DED from other inflammatory ocular surface disease; manufacturer/studies document limitations including sample-volume dependency.
Although AXIM reports sensitivity/specificity, the policy states these assays do not meet coverage criteria.
Standard clinical tests (TBUT, Schirmer, staining) are discussed as clinical assessments but specialized biomarker assays beyond osmolarity are not covered per this policy.
inv-03: Diagnostic Testing Criteria (Guideline-aligned) — Supported when combined with symptoms and other clinical findings; any one of specified homeostasis markers can confirm diagnosis in context
Diagnostic testing is supported when combined with symptoms and other clinical findings; any one of specified homeostasis markers can confirm diagnosis if correlated with symptoms.
TFOS DEWS III consensus: any one marker may confirm diagnosis when correlated with symptoms.
TFOS DEWS III recommendation to subtype aqueous-deficient versus evaporative disease.
DTS panel and cited studies note MMP-9 usefulness primarily in more severe disease and sample-volume limitations.
TFOS DEWS III consensus supports osmolarity as an early global marker and for therapeutic monitoring; interpret alongside clinical findings due to variability.
All diagnostic tests for dry eye disease that are not explicitly discussed in this policy (beyond tear osmolarity) are stated as not meeting criteria due to insufficient published scientific literature demonstrating they are required and beneficial for diagnosis or treatment. This exclusion applies to specialized tear assays and other investigational tests when they are submitted as covered diagnostic services without supporting evidence.
Point-of-care MMP‑9 immunoassays such as InflammaDry can produce false‑negative results when tear sample volume is markedly low (manufacturer guidance and published data note sample volumes <6 μL may impair reliability). In clinical contexts with reduced tear secretion (for example, Sjögren syndrome), a negative InflammaDry result may not exclude ocular surface inflammation and should be interpreted cautiously.
Within the extracted document fragments provided, there are no additional explicit coverage exclusions beyond those already stated for specific tests; publication history and governance approval are documented but do not add further exclusion language in the cited sections.
The policy excerpts designate testing for MMP‑9, lactoferrin, and IgE in tears as not meeting criteria and therefore not medically necessary when billed as covered diagnostic tests. These assays are identified separately from tear osmolarity and are listed as not meeting criteria in the indications/limitations section.
The American Academy of Ophthalmology notes that no single test is adequate to establish a diagnosis of dry eye disease; test results should be interpreted in the context of symptoms and other clinical findings. Isolated use of a single point‑of‑care assay without corroborating examination and symptom correlation is therefore insufficient for diagnosis.
The extracted fragments do not contain an explicit phrase using the term 'not medically necessary' beyond statements that certain tests do not meet criteria; no additional explicit NMN wording was found in the cited sections.
Procedure Codes and Diagnostic Thresholds
| 82785 | Gammaglobulin (immunoglobulin); IgE. |
| 83516 | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method. |
| 83520 | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified. |
| 83861 | Microfluidic analysis utilizing an integrated collection and analysis device, tear osmolarity |
Provider Actions, Documentation, and Billing Considerations
Prior authorization / coverage headline: Tear osmolarity meets criteria; other biomarkers do not
Testing of tear osmolarity meets coverage criteria when used for patients suspected of having dry eye disease, to help determine severity, or to monitor effectiveness of therapy; specific tear biomarkers (MMP-9, lactoferrin, IgE) do not meet criteria. Ensure documentation links the osmolarity result to the clinical indication and intended use (severity determination or therapy monitoring).
Prior authorization may apply to listed assay codes (82785, 83516, 83520, 83861)
Procedure codes for immunoassays and tear osmolarity are listed (82785, 83516, 83520, 83861); if the payer requires prior authorization for diagnostic lab/procedure codes, submit clinical documentation of symptoms and concordant clinical findings.
Prior authorization: No specific PA rules stated in this policy excerpt
No explicit prior authorization requirements are specified in the extracted sections of this policy; providers should follow member benefit documents and payer-specific rules for any PA obligations.
Therapy context: Diagnostic testing used alongside standard DED management
Initial DED management centers on artificial tears and environmental measures; anti-inflammatory topical therapies (e.g., topical cyclosporine, lifitegrast) are used as supplementary or advanced treatments and testing may be used to guide therapy selection or monitoring.
- First-line: artificial tears, environmental modification
- Advanced: topical cyclosporine A, lifitegrast, corticosteroids as clinically indicated
No step therapy specified for diagnostic testing
No explicit step therapy requirements for diagnostic testing are specified in the extracted sections of this policy.
Step therapy: None specified in policy fragments
The document does not specify step therapy sequences for diagnostic assays; providers should follow standard clinical pathways and payer-specific medication PA/step policies for therapies.
Documentation and coding accuracy: Submit accurate clinical and coding documentation
Providers must submit accurate documentation of services performed, code claims according to industry standards, and support medical necessity; claims lacking appropriate documentation or incorrect coding may be denied or recouped.
- Follow CPT, ICD-10, CMS, and other coding/billing guidelines when submitting claims
- Retain clinical records supporting the medical necessity of the test
Correlate tests with clinical findings: Combine assay results with symptoms and other tests
Document diagnostic test results in the context of patient symptoms and other clinical findings (e.g., TBUT, ocular surface staining, Schirmer test) when using point-of-care assays to support interpretation and treatment decisions.
- Record symptom questionnaires (e.g., OSDI, DEQ-5) and objective tests alongside assay results
- Note how the assay result affected diagnosis, severity assessment, or management
References to support clinical documentation: Cite guideline and device sources
Use cited evidence and device resources to support clinical documentation and medical necessity: TFOS DEWS II/III reports, AAO PPP, point-of-care test manuals, FDA summaries, and referenced studies are appropriate sources to reference in the medical record.
- TFOS DEWS II/III consensus reports and AAO Preferred Practice Pattern
- Device user manuals and FDA summaries (e.g., TearLab/ScoutPro, InflammaDry references)
Denial triggers: MMP-9, lactoferrin, IgE and other non-covered biomarker tests
Testing for MMP-9 (InflammaDry), lactoferrin, IgE, and other dry eye biomarker tests listed as not meeting criteria may be at risk for denial when billed as covered diagnostic tests.
- Policy states MMP-9, lactoferrin, and IgE testing DO NOT MEET CRITERIA
- All other testing not discussed also DOES NOT MEET CRITERIA
Sample-volume dependent false-negatives: InflammaDry may be false-negative if tear volume <6 μL
Be aware that MMP-9 immunoassays (e.g., InflammaDry) are sample-volume dependent: manufacturer/study data note that sample volumes <6 μL can produce false-negative results, potentially rendering the test non-diagnostic and subject to denial if performed without appropriate technique or documentation.
- Jun et al. found reduced reliability with small tear volumes; manufacturer notes <6 μL may yield false-negatives
- Document specimen adequacy when recording negative MMP-9 results
Prior/Denial note: No other denial criteria present in these fragments
Within the provided document fragments no additional denial criteria are specified; follow the policy statements above and payer rules when determining test appropriateness.
Background on Dry Eye Disease
Dry eye disease (DED) is a multifactorial disorder of the ocular surface characterized by loss of tear film homeostasis manifesting as tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities. Diagnosis is challenging because no single gold‑standard test exists; evaluation commonly combines patient symptoms, questionnaires, and multiple objective measures (for example, tear break‑up time, staining, Schirmer testing, and tear osmolarity) to establish disrupted homeostasis.
Definitions and Test Descriptions
References, Regulatory Status, and Revision History
Policy underwent governance review and was last reviewed/approved by Oscar Health clinical governance.
Policy became effective for coverage determinations for evaluation of dry eyes (includes criteria for tear osmolarity and biomarker testing).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.